Rating Change
BTIG reiterated its Buy rating on Cullinan Therapeutics, Inc. (NASDAQ:CGEM) on October 28, 2026.
BTIG reiterated its Buy rating on Cullinan Therapeutics, Inc. (NASDAQ:CGEM) on October 28, 2026.

At publication ·
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) · reiterate
At a glance
BTIG reiterated its Buy rating on Cullinan Therapeutics, Inc. (NASDAQ:CGEM) on October 28, 2026.
Cullinan Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $15.47 with a market capitalization of $730.2M. The stock has gained 91.2% over the past 52 weeks.
Analyst coverage from BTIG provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Cullinan Therapeutics, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 28, 2026 | BTIG | Buy | N/A |
| Oct 19, 2026 | BTIG | Buy | N/A |
| Oct 02, 2026 | HC Wainwright & Co. | Buy | N/A |
| Sep 25, 2026 | HC Wainwright & Co. | Buy | N/A |
| Sep 25, 2026 | BTIG | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View CGEM Stock Page
A rating of Buy from BTIG reflects the analyst's outlook on Cullinan Therapeutics, Inc. (NASDAQ:CGEM). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the CGEM forecast page.
Current market data
NASDAQ · CGEM
$15.03
Down: -$0.42 · -2.72%
Live quote updated
Keep reading
analyst ·
analyst ·
analyst ·
sec_filing ·